Search

Displaying results 7801 - 7810 of 9886 in total
  1. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. … For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.

    Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine
  2. Drug

    Acebutolol

    go.drugbank.com/drugs/DB01193
    ApprovedInvestigational

    A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors.

    Products: Nu-acebutolol - Tab 100mg, Nu-acebutolol - Tab 400mg
  3. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors.

    Products: Nu-zopiclone, Nu-zopiclone Tablets - 7.5mg
  4. Drug

    Fomepizole

    go.drugbank.com/drugs/DB01213
    ApprovedVet approved

    Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Dantrolene

    go.drugbank.com/drugs/DB01219
    ApprovedInvestigational

    Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.

  6. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

  7. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).

  9. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  10. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index